Growth Metrics

Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Gross Profit data on record, last reported at $297.2 million in Q4 2025.

  • For Q4 2025, Gross Profit rose 13.05% year-over-year to $297.2 million; the TTM value through Dec 2025 reached $1.1 billion, up 9.1%, while the annual FY2025 figure was $1.1 billion, 9.1% up from the prior year.
  • Gross Profit reached $297.2 million in Q4 2025 per AMRX's latest filing, up from $274.0 million in the prior quarter.
  • Across five years, Gross Profit topped out at $297.2 million in Q4 2025 and bottomed at $166.4 million in Q4 2021.
  • Average Gross Profit over 5 years is $225.4 million, with a median of $217.7 million recorded in 2022.
  • Peak YoY movement for Gross Profit: skyrocketed 48.6% in 2021, then decreased 11.87% in 2023.
  • A 5-year view of Gross Profit shows it stood at $166.4 million in 2021, then grew by 29.44% to $215.4 million in 2022, then dropped by 11.87% to $189.8 million in 2023, then soared by 38.48% to $262.9 million in 2024, then increased by 13.05% to $297.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $297.2 million in Q4 2025, $274.0 million in Q3 2025, and $286.3 million in Q2 2025.